Reprogramming the Tumor Microenviroment to Activate an Immune Response
Randy Schatzman, CEO of Bolt Biotherapeutics, discusses the company’s immune-stimulating antibody conjugates, the case for activating both the innate and adaptive immune systems to fight cancer, and the company’s lead experimental therapy for HER2 positive cancers.